SMITHKLINE LYME DISEASE VACCINE PHASE III TRIAL SHOULD BE COMPLETE IN THREE TO SIX MONTHS; SB VACCINES NEARING $1 BIL. IN SALES, EXECS TELL ANALYSTS
Executive Summary
SmithKline Beecham's two-year Phase III Lyme disease vaccine study should be completed in the next three to six months, Senior VP Jean Stephenne told analysts at an Oct. 30 meeting in New York City.